Candel Therapeutics (CADL)
NASDAQ:CADL
CADL Stock Chart & Stats
$4.98
$0.00(0.00%)
At close: 4:00 PM EST
$4.98
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.25 - $7.25
Previous CloseN/A
Volume524.53K
Average Volume (3M)1.55M
Market Cap
$364.77M
Enterprise Value$155.58M
Total Cash (Recent Filing)$119.73M
Total Debt (Recent Filing)$1.90M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
May 07, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding73,246,925
10 Day Avg. Volume1,237,701
30 Day Avg. Volume1,548,386
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-184.12
Enterprise Value/Ebitda-3.28
Forecast
1Y Price Target
$19.40Price Target Upside289.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Commercial ReadinessInstitutional equity and royalty financings plus a term loan strengthen the balance sheet, while a scaled manufacturing process and quality testing support a smoother transition from clinical development to commercial launch.
Clinical Survival EvidenceExtended follow-up in Phase 2a shows a durable long survival tail in difficult-to-treat non-small cell lung cancer patients, supporting movement toward a registrational study and increasing the therapy's commercial opportunity.
Immune Activation And MechanismTumor biomarker analyses demonstrate increased interferon signaling, activation of antigen-presenting cells, and expanded T-cell receptor diversity, indicating strong immune reactivation that may broaden patient applicability.
Bears Say
Dilution And Future Revenue ImpactA recent equity offering diluted existing shareholders and the royalty financing assigns a capped share of future U.S. sales to an external party, reducing per-share value and limiting upside from future revenue.
Pivotal Trial Design UncertaintyAmbiguity over pivotal trial design and whether biomarker-based patient selection will be required creates execution and prioritization risk between prostate and lung programs.
Regulatory Approval RiskThe FDA could request additional clinical data or different endpoints to support approval, which would complicate filings and potentially delay regulatory timelines.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $4.25 and its highest was $7.25 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $364.77M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 34 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.296.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 73,246,925 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -2.353%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.40 (289.56% Upside)
$19.40 (289.56% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 18.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.64%
12-Months-Change
Fundamentals
Return on Equity
-51.44%
Trailing 12-Months
Asset Growth
17.26%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Stock 12 Month Forecast
Average Price Target
$19.40
▲(289.56% Upside)
Technical Analysis
Tonix Pharma
―
Quantum-Si
―
Humacyte
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
9.52% Insiders
13.91% Mutual Funds
8.21% Other Institutional Investors
62.76% Public Companies and
Individual Investors